NanoViricides (NNVC) Retains Biologics Consulting Group to Prepare for IND

QualityStocks would like to highlight NanoViricides (OTCBB: NNVC), a development stage company that is creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

In the company’s news yesterday,

NanoViricides announced its consulting agreement with Biologics Consulting Group Inc. (BCG), in which the two companies will prepare for submission of Investigational New Drug (IND) applications to the U.S. FDA for NanoViricides’ nanoviricides® drug candidates.

BCG is an international consulting firm providing national and international regulatory and product development assistance for the development and commercial production of drug, biological and device products.

NanoViricides noted the advances and efforts it has made to get its anti-influenza drug candidates to the pre-IND and IND stages. From here on out, the company has engaged BCG to facilitate the FDA review and approval process, as well as to advise the company on the pre-IND application and development activities to follow.

NanoViricides previously reported success in its FluCide™ drug candidates in pre-clinical animal studies, and the company says it remains on track to develop FluCide®.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.